Johanna M Pfeil (J M Pfeil)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Combination Therapy

Optical Coherence Tomography

Age Related Macular Degeneration

Top Venues

Acta ophthalmologica

Archives of disease in childhood. Fetal and neonatal edition

This page only lists publications with an associated author ORCID identifier.

Publications

Tim U Krohne, Alexandra T Camp, Johanna M Pfeil, Andreas Müller, Andreas Stahl, Wolf A Lagrèze, Jeany Q Li, null null
Retinopathy of prematurity in Germany over 13 years: incidences, treatment preferences and effects of national guideline changes. Archives of disease in childhood. Fetal and neonatal edition (2024)
Tim U Krohne, Alexandra T Camp, Johanna M Pfeil, Andreas Müller, Andreas Stahl, Wolf A Lagrèze, Jeany Q Li, null null
Retinopathy of prematurity in Germany over 13 years: incidences, treatment preferences and effects of national guideline changes. Archives of disease in childhood. Fetal and neonatal edition (2024)
K Winter, Johanna M Pfeil, H Engmann, S Aisenbrey, B Lorenz, K Hufendiek, H Breuss, M Khattab, D Süsskind, V Kakkassery, Wolf A Lagrèze, T Barth, Raffael G Liegl, M C Bründer, C Skevas, I Goldammer, B Glitz, E Michalewicz, Tim U Krohne, I R Bartmann, Andreas Stahl, null null
Comparability of input parameters in the German Retina.net ROP registry and the EU-ROP registry - An exemplary comparison between 2011 and 2021. Acta ophthalmologica (2023)
Martin Busch, Johanna M Pfeil, Merlin Dähmcke, Tara Brauckmann, Rico Großjohann, Viola Chisci, Elisabeth Hunfeld, Sonja Eilts, Wael Omran, Ewa Morawiec-Kisiel, Daniel Schulz, Sebastian Paul, Allam Tayar, Marie-Christine Bründer, Bastian Grundel, Martin Küstner, Andreas Stahl
Anti-drug antibodies to brolucizumab and ranibizumab in serum and vitreous of patients with ocular disease. Acta ophthalmologica 100 (8) (2022)
Andreas Stahl, Marie-Christine Bründer, Wolf A Lagrèze, Fanni E Molnár, Teresa Barth, Nicole Eter, Rainer Guthoff, Tim U Krohne, Johanna M Pfeil, null null
Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study. Acta ophthalmologica (2021)